Overcoming negative predictions of microRNA expressions to gemcitabine response with FOLFIRINOX in advanced pancreatic cancer patients

Konstantin Schlick,Florian Hohla,Frank Hamacher,Hubert Hackl,Clemens Hufnagl,Steiner Markus,Teresa Magnes,Simon Peter Gampenrieder,Thomas Melchardt,Stefan Stättner,Cornelia Hauser-Kronberger,Richard Greil,Gabriel Rinnerthaler

Overcoming negative predictions of microRNA expressions to gemcitabine response with FOLFIRINOX in advanced pancreatic cancer patients

2020

Konstantin Schlick
Florian Hohla
Frank Hamacher
Hubert Hackl
Clemens Hufnagl
Steiner Markus
Teresa Magnes
Simon Peter Gampenrieder
Thomas Melchardt
Stefan Stättner
Cornelia Hauser-Kronberger
Richard Greil
Gabriel Rinnerthaler

FOLFIRINOX is superior to gemcitabine in patients with pancreatic cancer, but this regimen is associated with toxicity and biomarkers for response are warranted. MicroRNAs can mediate drug resistan...

Keywords:

Toxicity
FOLFIRINOX
Gemcitabine
Regimen
Pancreatic cancer
Drug
Oncology
microRNA
Biomarker (medicine)
Internal medicine
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations